FDA Cites Contaminated Loratadine Study In MDS Pharma Letter
This article was originally published in The Tan Sheet
Executive Summary
MDS Pharma Services' "inadequate" approach to investigating contamination in a loratadine bioequivalence study will place future data submissions from the firm under increased scrutiny from FDA, according to a recent letter to the company
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning